Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer

October 18, 2021 Auto Bot Clinical Trials, Innovent, Non-Small Cell Lung Cancer, P-III, Sintilimab 0

Shots:

  • The P-III ORIENT-31 study evaluates sintilimab with/out Byvasda + CT vs CT in a ratio (1:1:1) in patients with EGFR-mutated LA or metastatic nonsq. NSCLC who have progressed following EGFR TKI treatment
  • The study has met its prespecified 1EPs of PFS at 1st interim analysis. In the ITT population, sintilimab + Byvasda & CT showed an improvement in PFS & Sintilimab + CT also showed PFS benefit over CT alone, the safety profile was consistent with that observed in previously reported studies of sintilimab & Byvasda & no additional safety signals were observed
  • Additionally, the regulatory submission is currently under review in China for sintilimab as 1L treatment of ESCC

Click here to­ read the full press release/ article | Ref: PR Newswire | Image: Fierce Pharma

The post Innovent Reports Results of Sintilimab in P-III ORIENT-31 Study for EGFR-Mutated Non squamous Non-Small Cell Lung Cancer first appeared on PharmaShots.